MedTrace Logo

Effects of Eplerenone on Left Ventricular Remodelling Following Heart Attack

NCT00132093 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2006-04-10

No results posted yet for this study

Summary

The purpose of this study is to ascertain whether treatment with the drug eplerenone, taken early after a heart attack, prevents or reduces some of the adverse changes that may otherwise naturally occur within the heart muscle, that lead ultimately to weakening of the heart muscle and premature death.

Conditions

Interventions

DRUG

Eplerenone

Sponsors & Collaborators

  • NHS Greater Glasgow and Clyde

    lead OTHER

Principal Investigators

  • Robin AP Weir, MBChB, BSc, MRCP · NHS Greater Glasgow and Clyde

  • Henry J Dargie, MBChB,FRCP · NHS Greater Glasgow and Clyde

  • John JV McMurray, FRCP,MD,FESC · University of Glasgow

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-04-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00132093 on ClinicalTrials.gov